+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the long-term safety, tolerability, and effectiveness of ML-007C-MA in adults with schizophrenia. This open-label Phase 2 study includes participants who have recently completed a previous related study or new participants enrolling directly. The study focuses on adults aged 18 to 65 diagnosed with schizophrenia who may benefit from ongoing pharmacotherapy and can maintain outpatient care. Participants will receive ML-007C-MA dosed at 2103 mg twice daily for up to 52 weeks. This single-group study does not involve placebo and assesses the medications impact over the treatment period. The study allows for continuous monitoring and adjustment based on the participants response and tolerability. During the study, participants will be involved in regular assessments to monitor safety and tolerability from the initial dose through the entire treatment period. Evaluations include clinical interviews, physical exams, ECGs, and laboratory tests to track any adverse effects or changes in health status. Researchers will also gather information from a reliable informant to support assessments. The total participation duration can be up to one year.

Age: 18Years - 65YearsAll GendersPhase 2
45 locations
L

Actively Recruiting

Researchers are studying the long-term safety and tolerability of the drug NBI-1065845 when used alongside other treatments for adults with Major Depressive Disorder MDD. This Phase 3 trial focuses on participants who have moderate to severe recurrent MDD or persistent depressive disorder, particularly those who have not responded well to oral antidepressants in their current depressive episode. Participants will take NBI-1065845 tablets orally once a day as an additional treatment. The study is open-label and single group, meaning all participants receive the same treatment. The trial will observe participants over the course of one year while they take the medication. During the study, participants will undergo assessments to monitor any treatment-emergent adverse events from the start through week 52. Researchers will evaluate how well participants tolerate the medication and ensure their safety throughout the treatment period. The total participation duration corresponds to the one-year treatment and monitoring phase.

Age: 18Years +All GendersPhase 3
120 locations
A

Actively Recruiting

Researchers are evaluating the effects of NBI-1117568 on behavioral and psychological symptoms in adults diagnosed with schizophrenia who require inpatient hospitalization. This Phase 3 study compares NBI-1117568 to a placebo to assess its impact on symptom improvement. The trial is led by Neurocrine Biosciences and focuses on adults between 18 and 65 years old experiencing an acute episode or relapse of schizophrenia symptoms. Participants will be randomly assigned to receive either NBI-1117568 or a placebo once daily by mouth for 5 weeks, from Day 1 to Day 35. The study is designed as a double-blind, placebo-controlled trial, meaning neither the participants nor the researchers know which treatment is being given during the study period. During the study, participants will stay in an inpatient setting and be monitored closely. Researchers will measure changes in symptoms using the Positive and Negative Syndrome Scale PANSS total score at the beginning and end of the 5 weeks. They will also assess changes in severity using the Clinical Global Impression - Severity CGI-S score. Safety and tolerability will be tracked throughout the trial, which will continue until October 2027.

Age: 18Years - 65YearsAll GendersPhase 3
21 locations
G

Actively Recruiting

Researchers are studying the long-term safety of the drug NBI-1117568 in adults diagnosed with schizophrenia. This phase 3, open-label trial aims to understand how well participants tolerate this medication when taken daily over an extended period. The study is sponsored by Neurocrine Biosciences and focuses on monitoring treatment-emergent adverse events. Participants will receive NBI-1117568 orally once a day for up to 36 months. This single-group study does not include a placebo or comparator arm. The treatment duration allows researchers to assess safety and tolerability during continuous daily use over three years. During the study, participants will have regular assessments to monitor any adverse effects associated with the drug. Researchers will track the number of participants experiencing treatment-emergent adverse events throughout the 36-month period. The study includes adults aged 18 to 65 years who have a primary diagnosis of schizophrenia and reside in stable housing, and it excludes those with certain medical conditions or substance use disorders. Participants will be closely observed to ensure adherence to the study protocol and safety monitoring.

Age: 18Years - 65YearsAll GendersPhase 3
61 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness of iloperidone long-acting injection LAI compared to a placebo in preventing worsening symptoms in adults with schizophrenia. This is a Phase 3, double-blind, randomized withdrawal study sponsored by Vanda Pharmaceuticals, aiming to understand how well iloperidone LAI maintains symptom control in this population. The study begins with a 12-week stabilization phase where all participants receive open-label iloperidone, first as oral tablets for six weeks, followed by long-acting intramuscular injections for another six weeks. After stabilization, participants are randomly assigned to receive either iloperidone LAI or a matching placebo injection every few weeks for up to 52 weeks in a double-blind manner. Participants will be closely monitored throughout the study, including during the stabilization and randomized phases, to track the time until symptoms worsen. Researchers will assess changes in schizophrenia symptoms over the 52-week post-randomization period. Safety and adherence to the study drug will be observed, providing valuable information on the treatments ability to maintain symptom stability over time.

Age: 18Years - 65YearsAll GendersPhase 3
22 locations
P

Actively Recruiting

The trial investigates the use of KarXT XanomelineTrospium Chloride for preventing relapse in adults diagnosed with schizophrenia. Participants must have had schizophrenia for at least one year with recent hospitalization and persistent symptoms, evaluated by specific psychiatric scales. This Phase 3 randomized, double-blind, placebo-controlled study aims to assess how well KarXT maintains symptom control compared to placebo. Participants are randomly assigned to receive either KarXT or a placebo with specified doses given on set days. The study monitors participants over a period of up to approximately 43 weeks after randomization to evaluate relapse prevention. All treatments and follow-ups are masked to ensure unbiased assessment. During the study, participants undergo regular evaluations including psychiatric assessments using PANSS and CGI-S scores to measure symptom severity and relapse events. Safety is monitored through tracking of adverse events and special interest symptoms. The primary outcome measures the time from randomization to the first relapse. The total participation duration spans several months, with ongoing safety and efficacy assessments throughout the study period.

Age: 18Years - 65YearsAll GendersPhase 3
54 locations
R

Actively Recruiting

Researchers are evaluating lumateperone as an additional treatment for adults aged 18 to 65 years with major depressive disorder MDD who have not responded adequately to current antidepressant treatments. This phase 3, multicenter study is randomized, double-blind, and placebo-controlled, aiming to assess the efficacy and safety of lumateperone in this population. The study includes patients with moderate to severe depression diagnosed according to DSM-5 criteria, including those with psychotic features. Participants will be randomly assigned to receive either lumateperone 42 mg capsules or matching placebo capsules once daily for six weeks during the double-blind treatment period. The study consists of three distinct periods an initial screening lasting up to two weeks to determine eligibility, the six-week treatment phase with daily medication, and a one-week safety follow-up after the last dose to monitor any adverse effects. During the study, participants will undergo assessments including depression rating scales such as the Montgomery-Asberg Depression Rating Scale MADRS and Clinical Global Impression Scale-Severity. Safety evaluations will be conducted throughout, including a follow-up visit about one week after treatment ends. The total participation time may last up to nine weeks, encompassing screening, treatment, and safety monitoring.

Age: 18Years - 65YearsAll GendersPhase 3
69 locations
P

Actively Recruiting

Researchers are evaluating the efficacy of NBI-1065845 compared with a placebo as an additional treatment in adults with Major Depressive Disorder MDD. The study focuses on participants who have moderate to severe depression or persistent depressive disorder and who have not adequately responded to oral antidepressant treatments. This Phase 3, randomized, double-blind, placebo-controlled trial aims to assess how well NBI-1065845 improves symptoms of depression over the course of treatment. Participants will receive either NBI-1065845 tablets or matching placebo tablets, both administered orally once a day. The study treatment is given alongside participants ongoing oral antidepressant therapy, which they must continue at the same dose and frequency throughout the trial. The treatment period lasts for 56 days, during which participants are monitored closely. During the study, participants will undergo assessments including the Montgomery-sberg Depression Rating Scale MADRS to measure changes in depression symptoms, as well as evaluations using the Sheehan Disability Scale SDS and Clinical Global Impression-Severity Scale CGI-S at baseline and day 56. The trial includes safety monitoring and adherence to study procedures, with a total participation duration of at least 56 days.

Age: 18Years +All GendersPhase 3
18 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and treatment response of GXV813 in adults hospitalized with schizophrenia who are experiencing an acute episode. This Phase 2a study aims to better understand how GXV813 affects symptoms of schizophrenia compared to a placebo in a controlled hospital setting. Participants will be randomly assigned to receive either GXV813 or a placebo, both given orally. The study uses a parallel-group design with quadruple masking to minimize bias. Treatment and observations will last for up to 6 weeks during hospitalization, focusing on symptom changes and drug pharmacokinetics. During the study, participants will be closely monitored with psychiatric assessments including the Positive and Negative Symptom Scale PANSS and Clinical Global Impression-Severity CGI-S scale. Researchers will also track safety, tolerability, and drug levels in the blood. The total participation time is about 6 weeks, with regular evaluations to measure changes from baseline symptoms and any adverse events.

Age: 18Years - 65YearsAll GendersPhase 2
16 locations